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A CRISPR FUTURE FOR GENE-EDITING 
REGULATION:  A PROPOSAL FOR AN UPDATED 
BIOTECHNOLOGY REGULATORY SYSTEM IN AN 
ERA OF HUMAN GENOMIC EDITING 
Tracey Tomlinson* 
 
Recent developments in gene-editing technology have enabled scientists to 
manipulate the human genome in unprecedented ways.  One technology in 
particular, Clustered Regularly Interspaced Short Pallindromic Repeat 
(CRISPR), has made gene editing more precise and cost-effective than ever 
before.  Indeed, scientists have already shown that CRISPR can eliminate 
genes linked to life-threatening diseases from an individual’s genetic makeup 
and, when used on human embryos, CRISPR has the potential to permanently 
eliminate hereditary diseases from the human genome in its entirety.  These 
developments have brought great hope to individuals and their families, who 
suffer from genetically linked diseases.  But there is a dark side:  in the wrong 
hands, CRISPR could negatively impact the course of human evolution or be 
used to create biological weaponry.  Despite these possible consequences, 
CRISPR remains largely unregulated due to the United States’s outdated 
regulatory scheme for biotechnology.  Moreover, human embryo research, 
which is likely critical to maximizing the therapeutic applications of CRISPR, 
is not easily undertaken by scientists due to a number of federal and state 
restrictions aimed at preventing such research.  This Note examines the 
possible benefits and consequences of CRISPR and discusses the current 
regulations in both the fields of biotechnology and human embryo research 
that hamper the government’s ability to effectively regulate this technology.  
Ultimately, this Note proposes a new regulatory scheme for biotechnology 
that focuses on the processes used to create products using CRISPR, rather 
than the products themselves, with a focus on enabling ethical research using 
human embryos to maximize the potential benefits of CRISPR. 
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INTRODUCTION 
Twelve weeks after her birth, Layla Richards, an otherwise happy and 
healthy infant, was taken to the doctor after she began refusing milk.1  What 
followed was every parent’s worst nightmare:  Layla was diagnosed with an 
aggressive form of leukemia.2  After several rounds of chemotherapy and a 
bone marrow transplant failed to slow the disease, Layla’s parents and 
physicians resigned themselves to the inevitable and prepared to make 
Layla’s last few weeks as comfortable as possible.3  But when a researcher 
serendipitously located a few doors down from the cancer ward where Layla 
was admitted got wind of the situation, he proposed a novel treatment that 
had, up until that point, only been tested in mice.4  With the consent of her 
parents, Layla was injected with a vial full of an anonymous donor’s white 
blood cells that were programmed to recognize and kill cancer cells.5  Layla 
 
 1. Madhumita Murgia, How Scientists in Britain Are Deciding the Future of Humanity, 
NEWSWEEK (Dec. 28, 2016, 9:58 AM), http://www.newsweek.com/2017/01/06/gene-editing-
dna-crispr-revolution-kathy-niakan-britain-535858.html [https://perma.cc/J59P-EZA4]. 
 2. Id. 
 3. Id. 
 4. Id. 
 5. Id. 
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not only survived the treatment but went into remission within the month 
and, two years later, remains cancer free.6 
Until recently, Layla’s miraculous recovery would have been relegated to 
the pages of medical science-fiction novels.  Today, however, researchers are 
closer than ever before to making stories like Layla’s more commonplace 
thanks in large part to a tool called Clustered Regularly Interspaced Short 
Pallindromic Repeat (CRISPR), which enables scientists to manipulate the 
human genome with unprecedented precision.  Despite its promise, CRISPR 
is not without controversy.  Many of the potentially lifesaving therapies that 
scientists wish to research using this tool have been delayed or scrapped 
altogether because of complicated ethical questions and a general lack of 
regulation surrounding the technology.  This Note focuses on one particularly 
challenging piece of this ethical puzzle—the use of human embryos in 
CRISPR research—and proposes a path for regulation of the technology that 
balances ethical concerns with CRISPR’s promise to make medical miracles, 
like Layla’s, everyday realities. 
Since its discovery in 1993, CRISPR has excited scientists with the 
possibility that it could make genomic editing more accessible.7  At the time, 
researchers hypothesized that because CRISPR technologies are easier to use 
and more cost-effective than traditional gene-editing techniques,8 they would 
ultimately lead to the democratization of human genomic research.9  It was 
not until January 2013, however, that scientists working in the Broad Institute 
announced that they had successfully programmed CRISPR technologies to 
genomically edit human cells.10  This breakthrough signaled the beginning 
of the CRISPR craze and an onslaught of technological development.11  In 
2017 alone, CRISPR technologies enabled researchers to remove HIV from 
living animals,12 edit out Huntington’s disease in mice,13 slow the growth of 
cancerous cells,14 and open the door to the eradication of mosquito-borne 
diseases.15  Despite the incredible impact this technology could have on 
 
 6. Id. 
 7. See Eric S. Lander, The Heroes of CRISPR, 164 CELL 18, 18 (2016). 
 8. See, e.g., Dipankan Bhattacharya et al., CRISPR/Cas9:  An Inexpensive, Efficient Loss 
of Function Tool to Screen Human Disease Genes in Xenopus, 408 DEVELOPMENTAL BIOLOGY 
196, 197 (2015). 
 9. Feng Zhang, CRISPR:  The Democratization of Gene Editing, SCIENCE, Sept. 26, 
2014, at 3, 3. 
 10. See generally Le Cong et al., Multiplex Genome Engineering Using CRISPR/Cas 
Systems, 339 SCIENCE 819 (2013). 
 11. See generally Elizabeth Pennisi, The CRISPR Craze, SCIENCE, Sept. 26, 2014, at 15. 
 12. See generally Chaoran Yin et al., In Vivo Excision of HIV-1 Provirus by saCas9 and 
Multiplex Single-Guide RNAs in Animal Models, 25 MOLECULAR THERAPY 1781 (2017). 
 13. See generally Su Yang et al., CRISPR/Cas9-Mediated Gene Editing Ameliorates 
Neurotoxicity in Mouse Model of Huntington’s Disease, 127 J. CLINICAL INVESTIGATION 2719 
(2017). 
 14. See Zhang-Hui Chen et al., Targeting Genomic Rearrangements in Tumor Cells 
Through Cas9-Mediated Insertion of a Suicide Gene, 35 NATURE BIOTECHNOLOGY 543, 549 
(2017). 
 15. See generally Natapong Jupatanakul, Engineered Aedes aegypti JAK/STAT Pathway-
Mediated Immunity to Dengue Virus, 11 PLOS NEGLECTED TROPICAL DISEASES, Jan. 12, 2017, 
at 1. 
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human health, recent developments have made the unfettered use of CRISPR 
controversial.  Most notably, scientists from the Oregon Health & Science 
University (OHSU) announced in August 2017 that they successfully 
programmed CRISPR to correct a genetic mutation linked to heart failure in 
human embryos.16  This news reignited fears of “designer babies” and 
“playing God” that opponents of stem cell research in the mid-1990s 
commonly cited.17  The news also brought the question of CRISPR 
regulation to the forefront of national debate, as questions surrounding use of 
human embryos in research are particularly controversial. 
Despite these fears, CRISPR remains largely unregulated in the United 
States because the current regulatory regime for biotechnology is a 
convoluted system involving a number of different federal agencies, each 
with overlapping roles, which leads to widespread confusion as to which 
agency is responsible for a particular area of law.  Accordingly, researchers 
using CRISPR are often in the dark until they are readying products for 
market approval as to which laws will govern the product in which they have 
invested millions of dollars.  Scientists using human embryos as part of a 
CRISPR-driven research plan are incapable of receiving federal funding for 
the project, which leads them to either abandon research involving human 
embryos or seek private funding.18  These problems lead to somewhat 
discordant complications:  CRISPR research involving human embryos is 
stifled because of a lack of funding, yet researchers are free to bend ethical 
boundaries in the realm of gene editing using CRISPR if they can secure 
private funding.  These conflicting outcomes represent a worst-case scenario.  
Subsequently, the need to clarify the regulatory scheme for biotechnology 
products—like CRISPR—that may involve human embryos in the course of 
researching lifesaving treatments must be prioritized. 
This Note is organized in three Parts.  Part I begins by giving background 
information on CRISPR and its applicability to human health.  Part I then 
discusses key moments in the decades-long debate over human embryo 
research and concludes with an overview of the current biotechnology 
regulatory regime in the United States.  Part II discusses current proposals 
for biotechnology regulation and human embryo research regulation.  Part III 
evaluates these proposals and ultimately recommends a comprehensive 
regulatory scheme that will shift the United States away from the end-product 
focus promulgated by current biotechnology regulations toward a process-
oriented regime.  These recommendations endeavor to give the government 
more insight into CRISPR research in the United States without 
 
 16. See Hong Ma et al., Correction of a Pathogenic Gene Mutation in Human Embryos, 
548 NATURE 413, 418 (2017). 
 17. See, e.g., Robert Cook-Deegan & Jane Maienschein, Listening for the Public Voice, 
SLATE (Aug. 16, 2017, 4:17 PM), http://www.slate.com/articles/technology/future_tense/ 
2017/08/the_public_needs_to_weigh_in_on_the_ethics_of_genetically_engineering_humans
.html [https://perma.cc/KZC6-CJRZ]. 
 18. Sarah Webb, A Patchwork Quilt of Funding, NATURE (Nov. 1, 2007), 
https://www.nature.com/stemcells/2007/0711/071101/full/stemcells.2007.110.html 
[https://perma.cc/VZ24-P67H]. 
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unnecessarily hampering biomedical research and to create nationally 
mandated ethical standards for the use of human embryos in gene-editing 
research.  By offering suggestions for streamlining the regulatory process, 
this Note hopes to stimulate debate on CRISPR regulation and encourage 
policymakers to think critically about the future of human genome editing in 
the United States. 
I.  THE CURRENT STATE OF AFFAIRS:  CRISPR, 
HUMAN EMBRYO RESEARCH, AND 
BIOTECHNOLOGY REGULATION WITHIN THE UNITED STATES 
CRISPR is a naturally occurring molecule found in bacteria and is 
considered “the hallmark of a bacterial defense system.”19  In the field of 
gene editing, however, CRISPR is used as a catchall term for systems that 
enable researchers to program the CRISPR molecule to make precise cuts 
along a cell’s genome.20  Using CRISPR technologies, scientists can remove 
undesirable or harmful genetic sequences and replace them with neutral or 
beneficial genetic material.21  Contrasted with earlier “transgenic” 
techniques, which require the time consuming and expensive process of 
inserting the genetic material of a different species,22 CRISPR is much more 
precise, cost-effective, and straightforward.  Accordingly, CRISPR has 
enabled large numbers of scientists to delve into the world of gene editing, 
simultaneously raising questions about how this technology should be used.  
This Part addresses important background information regarding the current 
regulatory debate surrounding CRISPR by first discussing the development 
and possible applications of CRISPR, then focusing on the historic and 
current questions regarding human embryo research.  This Part concludes by 
explaining the current regulatory landscape for biotechnology in the United 
States. 
A.  The Who, What, Where, and How of CRISPR 
Understanding the need for CRISPR regulation requires a baseline 
understanding of how CRISPR works and, subsequently, why the 
development of this technology represents such a meteoric leap in the field 
of genomic editing.  The following section, aimed at a nonscientific audience, 
 
 19. Questions and Answers About CRISPR, BROAD INST., https://www.broadinstitute.org/ 
what-broad/areas-focus/project-spotlight/questions-and-answers-about-crispr 
[https://perma.cc/P2LK-HJYL] (last visited Aug. 24, 2018). 
 20. Id. 
 21. Id. 
 22. See, e.g., Michael Hernould et al., Male-Sterility Induction in Transgenic Tobacco 
Plants with an Unedited Atp9 Mitochondrial Gene from Wheat, 90 PROC. NAT’L ACAD. SCI. 
2370, 2371 (1993).  The oft-cited example of transgenic gene editing is the insertion of 
jellyfish DNA into rabbit embryos to create glow-in-the-dark rabbits. See Amanda Holpuch, 
Scientists Breed Glow-in-the-Dark Rabbits, GUARDIAN (Aug. 13, 2013, 17:49), 
https://www.theguardian.com/world/2013/aug/13/glow-in-dark-rabbits-scientists 
[https://perma.cc/L4MN-9H8J]. 
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explains first how CRISPR works and second, possible applications of 
CRISPR that would require human embryo research. 
1.  The Nuts and Bolts of CRISPR Technology:  How CRISPR Works 
In 1993, Spanish scientist Francisco Mojica noticed repeating sequences 
of genetic code separated by “spacers” in bacteria.23  Confused by the 
presence of these sequences, Mojica began investigating and eventually 
discovered that the spacers were remnants of genetic code from past viral 
invaders.24  This system of DNA sequences and spacers is a hallmark of the 
bacterial defense system and was given the name CRISPR by Mojica and his 
colleagues.25  Today, the term “CRISPR” is typically used to refer to the 
technologies researchers have developed over the past decade that enable 
genomic editing by manipulating the naturally occurring CRISPR to act as a 
pair of molecular scissors.26 
To understand these modern technologies, however, it is important to 
know how the naturally occurring CRISPR defense system found within 
bacteria works.  When a virus attacks a bacterium, the bacterium’s immune 
system sends out enzymes in response.27  In instances where the virus is 
successfully destroyed, the enzymes store a piece of the virus’s DNA in the 
spacers between the CRISPR DNA sequences.28  Should the same virus 
attack again, the bacterium’s immune system will be able to match the 
invading virus’s DNA with the stored portion and quickly kill the virus by 
cutting out the stored, matching sequence.29  To help visualize this process, 
imagine each portion of viral DNA that the bacterium stores is a barcode.  
When a new virus enters the cell, the bacterium scans all of the stored 
barcodes of previous invaders.  If one of the barcodes is a match, the 
bacterium can send out targeted enzymes that “snip” the matching barcode 
from the viral invader’s DNA, thereby killing the invader. 
The power of CRISPR stems from this ability to pinpoint and snip a DNA 
sequence at a precise location along the genome.  Indeed, scientists often 
liken CRISPR to a pair of “molecular scissors” that enables targeted genomic 
editing.30  This transformation of gene editing is particularly impressive 
when compared with earlier transgenic31 techniques developed in the 1980s.  
 
 23. See Lander, supra note 7, at 18. 
 24. See id. at 20. 
 25. See id. at 19. 
 26. Unless otherwise specified, this Note’s use of the term CRISPR refers to the 
technology—not the naturally occurring CRISPR molecule found in a bacterium. 
 27. See Fedor V. Karginov & Gregory J. Hannon, The CRISPR System:  Small RNA-
Guided Defense in Bacteria and Archaea, 37 MOLECULAR CELL 7, 9 (2010). 
 28. See id. at 10. 
 29. Ekaterina Pak, CRISPR:  A Game-Changing Genetic Engineering Technique, 
HARV. U.:  SCI. NEWS (July 31, 2014), http://sitn.hms.harvard.edu/flash/2014/crispr-a-game-
changing-genetic-engineering-technique/ [https://perma.cc/QS9S-9WCG]. 
 30. See generally Guy Riddihough, CRISPR Cas9 Molecular Scissors, 351 SCIENCE 867 
(2016). 
 31. Transgenic gene editing literally means across-species gene editing and occurs when 
“a gene is moved from one non-closely related species to another.” Keith Edmisten, What Is 
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While transgenic gene editing enabled scientists to insert DNA at specific 
locations in embryonic cells, “the process was inefficient—requiring 
selection and screening to identify the one-in-a-million [viable] cells.”32  
This process often resulted in DNA insertion at the wrong point along the 
genome, which led scientists to determine that “[t]he secret to efficient 
genome editing . . . was to find a reliable method to produce a . . . break at 
any desired location.”33  With the discovery of CRISPR, scientists finally 
saw a tool that they believed would help them modernize genomic editing 
and began working to harness CRISPR’s ability to cut DNA sequences at 
precise locations.34 
While scientists had long hypothesized that a deeper understanding of 
CRISPR would advance the field of gene editing, it was not until 2011 that 
researchers finally discovered all of the components necessary to make this 
theory a reality.35  And in 2013, Feng Zhang and his team from the Broad 
Institute successfully adapted CRISPR for genomic editing in human and 
mouse cells.36  No longer was CRISPR simply an obscure immune defense 
system relegated to bacterial cells—the term now referred to a powerful 
technology capable of editing the human genome in unprecedented ways.37 
Broadly, CRISPR technologies rely on two components.  The first 
component is the enzyme Cas9, which is responsible for actually cutting 
DNA strands.38  The second component is “a guide [RNA] molecule that 
directs Cas9 to a specific target like a genetic GPS system.”39  Once the Cas9 
enzyme has snipped the DNA sequence at the site directed by the guide 
molecule, the CRISPR user then has the option to remove, replace, or insert 
 
the Difference Between Genetically Modified Organisms and Genetically Engineered 
Organisms, N.C. ST. U., https://agbiotech.ces.ncsu.edu/q1-what-is-the-difference-between-
genetically-modified-organisms-and-genetically-engineered-organisms-we-seem-to-use-the-
terms-interchangeably/ [https://perma.cc/SNF9-LCPH] (last visited Aug. 24, 2018). 
 32. Lander, supra note 7, at 24. 
 33. Id. at 24. 
 34. See id. 
 35. CRISPR Timeline, BROAD INST., https://www.broadinstitute.org/what-broad/areas-
focus/project-spotlight/crispr-timeline [https://perma.cc/EXR9-3UB9] (last visited Aug. 24, 
2018). 
 36. See Cong, supra note 10, at 822; see also Prashant Mali et al., RNA-Guided Human 
Genome Engineering via Cas9, 339 SCIENCE 823, 823 (2013). 
 37. Briefly, scientists program CRISPR by “design[ing] and synthesiz[ing] short RNA 
molecules that match a specific DNA sequence . . . .  Then . . . this ‘guide RNA’ shuttles 
molecular machinery to the intended DNA target.  Once localized to the DNA region of 
interest, the molecular machinery can silence a gene or even change the sequence of a gene.” 
Pak, supra note 29. 
 38. See Josiane E. Garneau et al., The CRISPR/Cas Bacterial Immune System Cleaves 
Bacteriophage and Plasmid DNA, 468 NATURE 67, 69–70 (2010). 
 39. Ed Yong, CRISPR’s Most Exciting Uses Have Nothing to Do with Gene Editing, 
ATLANTIC (Jan. 5, 2016), https://www.theatlantic.com/science/archive/2016/01/the-most-
exciting-uses-of-gene-editing-technology-involve-no-editing/422619/ [https://perma.cc/ 
YHX5-EDLQ]; see also Haroon Butt et al., Efficient CRISPR/Cas9-Mediated Genome Editing 
Using a Chimeric Single-Guide RNA Molecule, 8 FRONTIERS PLANT SCI. 1441, 1442 (2017). 
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genomic material into the cell.40  In this way, CRISPR technologies enable 
scientists to precisely locate genes they would like to change and program 
the enzyme to target those genes.  These developments make CRISPR the 
most advanced gene-editing technology currently available and enable 
scientists to edit the human genome in previously impossible ways, which 
many believe will lead to the development of lifesaving medical 
advancements.41 
2.  CRISPR Could Potentially Expedite Medical Advancement 
for the World’s Most Challenging Diseases 
Since 2013, scientists around the world have continually refined CRISPR 
technology to make it even more precise.  Today, CRISPR gene editing “can 
be likened to editing a sentence with a word processor to delete words or 
correct spelling mistakes.”42  Scientists using the technology have “mutate[d] 
several suspected cancer genes simultaneously in the somatic cells of adult 
mice . . . .  [They] have also corrected disease-causing gene defects in adult 
mice, such as the mutations that cause hemophilia and sickle cell anemia.”43  
And in July 2017, scientists at OHSU reported that they successfully edited 
human embryos, removing a genetic mutation that causes heart failure in 
infants.44  The success of this experiment brought concerns over gene editing 
to the forefront of national debate, particularly with regard to the ethics of 
conducting experiments on human embryos.45  To illustrate the promise of 
CRISPR, this section details recent CRISPR experiments as well as potential 
applications for human health.46 
 
 40. See generally S. Antony Ceasar et al., Insert, Remove or Replace:  A Highly Advanced 
Genomic Editing System Using CRISPR/Cas9, 1863 BIOCHIMICA ET BIOPHYSICA ACTA 2333 
(2016). 
 41. See, e.g., Andrew Scott, How CRISPR Is Transforming Drug Discovery, 555 NATURE 
OUTLOOK, Mar. 7, 2018, at S10, S10; Victor Tangermann, A CRISPR Future:  Five Ways 
Gene Editing Will Transform Our World, FUTURISM (Jan. 30, 2018), https://futurism.com/ 
crispr-genetic-engineering-change-world/ [https://perma.cc/5ZBH-XSJY]. 
 42. Pak, supra note 29. 
 43. Jon Cohen, “Any Idiot Can Do It.”  Genome Editor CRISPR Could Put Mutant Mice 
in Everyone’s Reach, SCIENCE (Nov. 3, 2016, 10:00 AM), http://www.sciencemag.org/ 
news/2016/11/any-idiot-can-do-it-genome-editor-crispr-could-put-mutant-mice-everyones-
reach [https://perma.cc/S4UN-GAEW]. 
 44. See Ma et al., supra note 16, at 418. 
 45. See, e.g., Cook-Deegan & Maienschein, supra note 17. 
 46. Notably, CRISPR has been used extensively to edit crops and animals for food sources 
and is subsequently a critical component of the discussion surrounding genetically modified 
organisms (GMOs).  For further reading on CRISPR and GMOs, see Sarah Zhang, CRISPR 
Could Usher in a New Era of Delicious GMO Foods, ATLANTIC (Sept. 19, 2016), 
https://www.theatlantic.com/health/archive/2016/09/gmo-food-crispr-cabbage/500528/ 
[https://perma.cc/G8ZR-GG3Z]. 
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a.  CRISPR’s Precision Could Lead to Cures for 
Monogenic Diseases like Sickle-Cell Anemia 
CRISPR’s most straightforward therapeutic application is in the field of 
monogenic47 diseases—such as cystic fibrosis, sickle-cell disease (SCD), and 
Duchenne muscular dystrophy.48  Monogenic diseases are the result of a 
single mutation along the human genome, which means that absent this 
mutation, the disease would not exist.49  Scientists have long hypothesized 
that gene editing could rid the world of monogenic diseases but have lacked 
precise tools for the task.50  The discovery of CRISPR, and its ability to 
precisely locate and delete genetic mutations, brings the scientific 
community closer than ever before to the possible eradication of a number of 
debilitating monogenic diseases.51 
SCD is one such monogenic disease that is caused by a mutation in a single 
nucleotide in human DNA that codes for hemoglobin52—namely, there is “a 
T where an A should be.”53  This mutation leads to the creation of sickle-
shaped cells that stick together and cause buildups of cells.54  As a result of 
these buildups, parts of the body are deprived of oxygen and blood vessels 
are blocked, which causes an individual with SCD to experience “chronic 
anemia, severe pain episodes, . . . progressive damage to vital organs such as 
the brain, lung, and kidney,” and, ultimately, premature death.55  The only 
cure currently available for SCD involves cell transplantation to the SCD 
patient from a matching donor, a process that “has been used sparingly 
because of the difficulty in identifying donors, risks associated with the 
toxicity of the transplant regimen . . . and potentially fatal graft-versus-host 
disease.”56 
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Fortunately, this depressing prognosis may soon be a relic thanks to 
research conducted by a group of American scientists who, in 2016, 
successfully edited SCD-afflicted human cells in mice models using 
CRISPR.57  In the first stage of this experiment, the researchers found that 
they could repair up to 25 percent of the affected cells using CRISPR, far 
surpassing the 2–5 percent threshold at which most patients display clinical 
improvement.58  This efficacy dropped to 5 percent in the second stage of the 
experiment when the corrected cells were then engrafted into mice models,59 
leading one of the study’s authors to caution against moving forward with 
clinical trials in humans and argue that “it would be best to improve 
efficiency before [this technology] is deployed in people.”60  Undeterred by 
this warning, SCD patient advocacy groups have pushed for clinical trials in 
humans, and the National Institutes of Health (NIH) launched a study in 2017 
examining current opinions of CRISPR among SDC patients, family 
members of patients, and SCD-related healthcare providers.61  SCD is thus 
an example of one disease that could possibly be eradicated through the use 
of CRISPR therapeutics. 
b.  CRISPR’s Ability to Permanently Alter Heritable Traits Could Lead to 
the Complete Eradication of Hereditary Diseases 
One of the most significant capabilities of CRISPR as compared to other 
gene-editing technologies is its ability to create heritable traits that can be 
passed from generation to generation through the manipulation of what are 
known as germline cells.62  Germline cells are responsible for the traits that 
are passed down from generation to generation and are thus quite different 
from somatic cells, which are nonheritable and unique to an individual.63  In 
Layla Richards’s case, only her somatic cells were altered.64  This means that 
even though the cancer was successfully edited out of her blood cells, if she 
developed the cancer because of a genetic predisposition for childhood 
leukemia, Layla’s future children may still be at risk of inheriting the same 
predisposition. 
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CRISPR opens the door to the possibility of editing out such 
predispositions before a child is even born through editing germline cells 
within a human embryo or other precursor cell.65  The edits made to the 
embryo or precursor cell would then be passed down from generation to 
generation, as if they were part of the child’s naturally occurring genetic 
makeup.66  When it comes to the eradication of diseases like childhood 
leukemia, this idea sounds like a no-brainer, but scientists warn that in the 
wrong hands, these types of changes to heritable cells could have disastrous 
effects on the human genome.67 
The creation of a gene drive is one such possible application of CRISPR 
that could permanently alter the human genome.  A gene drive occurs when 
the odds of inheriting a particular trait are manipulated to nearly guarantee 
that the trait will be inherited.68  An offspring typically has a 50 percent 
chance of inheriting a particular trait from its parents, but inserting a gene 
drive created by CRISPR technologies would “circumvent these traditional 
rules” and “allow [the targeted traits] to spread to all members of a 
population.”69  For example, the use of gene drives to limit the reproductive 
capabilities of a particular species has been proposed for pest management 
programs and the eradication of mosquitos.70  But given the disastrous 
consequences that might befall ecosystems as a result of these changes, 
scientists have been reluctant to release these altered populations into the 
wild.71  The same concerns are present—although to a lesser degree given 
the slower pace of evolution—for the human species.  These concerns, 
coupled with the general need to conduct gene-drive research on human 
embryos, present significant ethical questions for policymakers and 
researchers that have not, as of yet, been addressed. 
3.  CRISPR and National Security:  Global Promise or Global Threat? 
Given the widespread effect CRISPR-edited cells could have on global 
ecosystems, James Clapper, the former Director of National Intelligence, 
raised concerns that CRISPR might pose national security issues.  Clapper 
contended that “[r]esearch in genome editing conducted by countries with 
different regulatory or ethical standards than those of Western countries 
probably increases the risk of the creation of potentially harmful biological 
agents or products,” leading to serious national security implications.72  The 
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concern is that the low cost and broad accessibility of CRISPR technology 
could lead to use of this technology for the creation of biological weapons.73  
One such example posited by the National Academies of Science (NAS) is 
that use of gene drives could lead to weaponized vectors, such as mosquitos, 
transmitting not only disease but potentially toxins as well.74  Accordingly, 
CRISPR technology in the wrong hands poses significant national security 
concerns. 
CRISPR is categorized as a “dual-use” technology—one that can be used 
for either ethical or malign purposes.  The U.S. government generally tries to 
influence such technologies “by controlling proliferation through export 
controls and international agreements . . . and by mitigating the risks of 
proliferation through other activities such as deterrence, disruption, and 
preparedness.”75  The Congressional Research Service contends that it is 
exactly the dual-use nature of CRISPR that makes it less of a threat than 
Clapper fears—it may increase the likelihood of biological warfare but it will 
concurrently be the most important tool available in mitigating that threat.76  
Accordingly, a deeper understanding of CRISPR is necessary to counteract 
potential misuse of the very same technology in bioterrorism. 
CRISPR has great potential to cure some of the most vexing diseases of 
the modern era, from genetically linked afflictions like SCD and Duchenne 
muscular dystrophy to hereditary cancer.77  It can potentially eradicate these 
diseases from the human genome in their entirety through the use of gene 
drives.78  These developments are, however, attended by serious ethical 
quandaries regarding the role humans should play in manipulating the human 
genome and pose serious threats to national security.  Additionally, many of 
these developments require the use of human embryos as part of the research 
and development process, which has previously caused strife within the 
United States79 and begs the question of how CRISPR research should be 
regulated. 
B.  A Historical Overview of Human Embryo Research in the United States 
As discussed in Part I.A, many of the most promising medical applications 
of CRISPR require the use of human embryos for research purposes.  
However, research involving human embryos has been an ethically fraught 
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issue for a number of decades, which has resulted in the erection of a number 
of federal barriers in the United States.  This section discusses the reasoning 
behind objections to human embryo research throughout recent American 
history to give a comprehensive picture of the current considerations 
policymakers must take into account when weighing the possible medical 
advancements made possible by CRISPR against concerns of constituents. 
1.  Key Issues for Opponents of Human Embryo Research 
Opponents of embryonic research typically cite moral and ethical concerns 
as the driving motivations for their disapproval.  These ethical concerns are 
founded in three main areas:  ways in which human embryos are acquired, 
how embryos are treated during research, and processes for destroying 
embryos when research is complete.  These points of opposition are 
discussed in turn. 
a.  Opponents of Human Embryo Research Are Concerned with How 
Embryos for Research Are Acquired 
Human embryos used for medical research are often acquired from in vitro 
fertilization (IVF) labs in situations where the owners of the embryos decide 
that particular embryos are unwanted.80  These embryos may be deemed 
unwanted for a number of reasons, including the finding of a serious, life-
threatening medical condition or the successful implantation of another 
embryo during a previous round of IVF (making the “extra” embryos created 
for the intended parent or parents unnecessary).81  Many endocrinologists 
estimate that there are roughly one million such embryos in storage facilities 
throughout the United States frozen in liquid nitrogen as families, clinics, and 
courts decide their fates.82  For some, the question of what to do with the 
unused embryos presents challenging questions about the definition of life,83 
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and for others the decision to donate the embryos to research labs is fairly 
straightforward.  Unfortunately, “[t]here are no national statistics on what 
happens with these leftover embryos.”84  Accordingly, trying to determine 
what the consensus surrounding use of unused embryos would—or should—
be poses challenges.  As a practical matter, fertility clinic employees report 
that many embryos “sit in storage indefinitely . . . costing $300 to $1,200 a 
year” in storage fees.85 
The debate surrounding the acquisition of human embryos for research 
mirrors the abortion debate.  Many religious organizations, including the 
Catholic Church, are opposed to the creation of embryos for IVF altogether 
because of a staunch belief that life begins at conception, while many 
“evangelicals accept in vitro, but believe frozen embryos have the right to 
full lives.”86  The U.S. legal system is of no help to individuals who are 
involved in disputes over embryos because the domestic IVF market remains 
largely unregulated,87 which often leaves those who would like to donate 
unused embryos in questionable legal territory. 
b.  Concerns Arise Surrounding the Physical Handling of 
Human Embryos During the Course of Research 
The debate over ethical use of human embryos continues even after the 
embryos have been donated for research.  Unlike other forms of human 
tissue, human embryos carry a more significant moral weight because of their 
potential for life.88  In a cross-cultural study, researchers found that the most 
common reason for donation was “a willingness to contribute to potentially 
curative medical research.”89  As the authors of the study point out, however, 
the reason behind the donation “raises a separate ethical concern about the 
patients’ understanding of the information they were given about the research 
goals,”90 underscoring the question of whether donors should be able to 
earmark embryos for certain types of research. 
There is also concern that fertility clinic employees may put undue 
pressure on people considering donation of embryos for research by 
essentially coercing them into the donation using their relative position of 
authority.  For this reason, researchers at Stanford University’s biobank came 
up with a process that enables “people to make this decision in the privacy 
of their own homes—without any interaction with clinic personnel or 
scientists who might benefit from the research.”91  The two-part procedure 
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advocated by the Stanford team begins with the clinic providing written 
information pertaining to embryo donation that the potential donor is free to 
take home or discard.  If the potential donor decides to move ahead with the 
donation, then she engages with a biobank staff member who follows a script 
to confirm the donor’s purported choices, including confirming the type of 
research the donor would like to support.92  Clinics across the country have 
adopted similar processes to ensure the decision to donate embryos to 
scientific research is done of the donor’s own volition and that the embryos 
are going towards research the donor personally supports.  But given the lack 
of regulation in the field, it remains an open question whether the donor 
would have any recourse should it be discovered that the embryos were used 
in a manner contrary to the donor’s wishes. 
c.  Many Groups Worry About How Embryos Are Destroyed 
at the Conclusion of Research 
Finally, there is controversy surrounding the ways in which embryos are 
destroyed after they have been used for scientific research.  Tracking the 
earlier debate surrounding acquisition of human embryos,93 opponents of 
embryo donation decry the destruction of embryos following research and 
claim a moral interest in the value of life they believe is inherent to 
embryos.94 
The immorality ascribed to destruction of embryos by opponents of this 
research is typically supported by one of three beliefs.  First, many opponents 
believe that beings with certain mental capacities should not be killed, often 
citing “consciousness, self-consciousness, sensitivity to pleasure and pain, 
and rationality” as components of this mental capacity.95  In the debate over 
embryonic research, however, this argument falls flat because scientists have 
shown that embryos do not develop feelings of pleasure or pain until sixteen 
weeks, consciousness until twenty-four weeks, development of self-
consciousness or rationality until after birth, and, in fact, “lack even the 
beginnings of a nervous system” until two weeks after conception.96 
Second, opponents often cite species membership as a reason for shying 
away from embryonic research and claim that, because these are human 
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embryos, they have greater moral value than embryos from other species.97  
But researchers are quick to point out that species membership should not 
have any more significance because “the assignment of beings to different 
species depends on various biological criteria that seem to lack any moral 
content or relevance.”98 
Finally, opponents often condemn the deprivation of a valuable future for 
an embryo as a reason for banning embryonic research.99  It is very unlikely, 
however, that embryos will go on to become humans capable of leading 
valuable lives; unused embryos are often “destined to languish in freezers 
until they are destroyed for some other reason.”100  Accordingly, the 
foundational concerns of opponents of embryonic research are untethered 
from the realities of embryonic life. 
Despite the foundational flaws of many opponents’ arguments, there are 
serious reasons to be concerned about unregulated embryonic research, 
particularly when embryos move beyond the early stages of development and 
into phases in which sensations of pain, pleasure, and consciousness begin 
developing.  To this end, researchers and governments around the world have 
long supported the fourteen-day rule, which draws a “legal and regulatory 
line in the sand” after which continued research on human embryos is 
impermissible.101  This rule mandates that after fourteen days in vitro, an 
embryo used for research must be destroyed—this timing was originally 
proposed because it “represents the earliest point at which an embryo’s 
biological individuation is assured.”102  The rule was not, however, “intended 
to be a bright line denoting the onset of moral status in human embryos” but 
was designed as “a public-policy tool . . . to carve out a space for scientific 
inquiry and simultaneously show respect for the diverse views on human-
embryo research.”103  In this regard, the fourteen-day rule has been 
considered successful, as evidenced by its international adoption.104  
Additionally, the existing rule assuages some of the concerns surrounding the 
destruction of human embryos at the conclusion of research. 
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2.  Historic and Current Restrictions on Human Embryo Research 
In the United States, research on human embryos has long been the subject 
of unease with the government responding to popular apprehension by 
instituting a variety of regulations and legislation intended to slow or halt 
embryonic research.  With the advent of CRISPR, however, this type of 
research is even more critical than ever before for to realize the promised 
benefits of this technology.105  With this tension in mind, this section 
explores historical attitudes surrounding research on human embryos and 
restrictions that both federal and state governments have placed on this type 
of research. 
a.  Restrictions at the Federal Level Focus on Cutting Off 
Funding Sources for Human Embryo Research 
In 1973, the U.S. Department of Health, Education, and Welfare106 
instituted a ban on research involving live human embryos that Congress 
expanded the following year to include embryos created using IVF.107  In 
1979 the federal advisory board responsible for reviewing “federally funded 
research on human sperm, eggs, and embryos” was disbanded because of 
pressure from anti-abortion groups.108  Presidents Ronald Reagan and 
George H. W. Bush later issued executive orders blocking all federal funding 
for research on human embryos, bowing to similar anti-abortion 
sentiments.109 
This ban was lifted in 1993 under President Bill Clinton, who, in an effort 
to effectuate embryo research, tasked the NIH with drafting guidelines for 
such research.110  The Human Embryo Research Panel presented these 
guidelines ten months later, recommending that human embryo research 
“should be allowed only if the embryos were less than 14 days old, if the 
studies could not be performed with animal embryos, and . . . if scientists 
could demonstrate a compelling reason why the studies should be 
performed.”111  This panel also determined that researchers should be 
allowed to create embryos specifically for medical research, meaning 
researchers would not be limited to surplus embryos from assisted 
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reproductive technology (ART) clinics.112  On the day the NIH met to vote 
on these guidelines, however, “President Clinton issued an Executive Order 
that government funded scientists would not be allowed to create human 
embryos for research.”113  As a result, the topic of embryonic research 
entered the spotlight, and politicians across the country—attempting to 
harness the political goodwill of anti-abortion groups—manifested their 
intentions to ban embryonic research. 
To this end, Congress passed the 1996 Dickey-Wicker Amendment as a 
bill rider to the annual omnibus appropriations bill, which prohibited the 
Department of Health and Human Services (“HHS”) from providing federal 
funding for research involving the “(1) creation of a human embryo or 
embryos for research purposes; or (2) research in which a human embryo or 
embryos are destroyed, discarded, or knowingly subjected to risk of injury or 
death.”114  Congress has renewed this bill rider every year since, creating 
substantial roadblocks for U.S. scientists looking to use human embryos in 
CRISPR research.115  To make matters even more complex, in 2016 the 
House of Representatives added an additional rider to the annual 
consolidations bill that prohibits the FDA from acknowledging applications 
“for an exemption for investigational use of a drug or biological product . . . 
in research in which a human embryo is intentionally created or modified to 
include a heritable genetic modification.”116  This means that the FDA must 
refrain from acknowledging that it even received such a submission. 
In 2011, President Obama attempted to lessen these restrictions on stem 
cell research by issuing Executive Order 13,505.117  This order underscored 
the importance of stem cell research and the need to support it with federal 
funding.118  Accordingly, the order directed the director of the NIH to 
“review existing NIH guidance and other widely recognized guidelines on 
human stem cell research, including provisions establishing appropriate 
safeguards, and issue new NIH guidance on such research that is consistent 
with this order.”119 
The NIH complied and new guidelines went into effect on July 7, 2009.120  
These guidelines loosened restrictions on human embryo research and 
enabled researchers to obtain federal funding for human embryo research, so 
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long as the embryos “were created using in vitro fertilization for reproductive 
purposes and were no longer needed for this purpose; [and] were donated by 
individuals who sought reproductive treatment . . . and who gave voluntary 
written consent for the human embryos to be used for research purposes.”121  
The guidelines did note, however, that funding projects where stem cells have 
been derived from human embryos remained prohibited because of the 
funding moratorium mandated by the Dickey-Wicker Amendment.122  
Importantly, these guidelines have been interpreted to apply to CRISPR-
based research due to the similar ethical conundrums posed by both fields.123 
b.  Restrictions at the State Level Are Wide-Ranging in Scope 
In addition to federal bans, many states regulate human embryo research.  
State approaches range from the statutes in eight states that actively 
encourage embryonic research to statutes that strictly forbid all forms of 
embryonic research.124  Massachusetts, for example, prohibits research on a 
live embryo or fetus and prohibits the creation of a fertilized embryo solely 
for research.125  Taken together, the state and federal restrictions that 
researchers must navigate when attempting to conduct research on human 
embryos erect substantial roadblocks, significantly slowing scientists’ 
abilities to advance therapeutic applications of gene-editing breakthroughs 
like CRISPR. 
3.  Current Funding Configurations for Human Embryo Research 
Despite the federal ban on funding for research on human embryos, private 
donations from foundations, organizations, and individuals have enabled 
researchers within the United States to conduct research on human 
embryos.126  Privately funded studies are subject to neither federal oversight 
nor state regulations, which means that the government is limited in its ability 
to control the research plans of these studies should researchers choose to 
ignore consensus-driven ethics in the field of genomic editing.127  In 2001, 
the American Academy of Pediatrics criticized this lack of oversight, stating 
that it “does little to address many of the ethical concerns, and . . . may limit 
the potential for this research to be valuable to large segments of society, 
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such as children.”128  But in the sixteen intervening years since this critique, 
government officials have taken no further steps to limit gene editing funded 
by private entities.  Indeed, the OHSU study that reignited this debate in the 
CRISPR context was privately funded.129  This lack of oversight leads to 
serious questions about how exactly the U.S. government should regulate 
research to ensure abusive use of CRISPR technologies does not threaten 
either societally endorsed applications of the technology or national 
security.130 
Ultimately, the current state of regulation surrounding human embryo 
research leaves scientists in this field with one option:  seek private funding.  
Absent private funding, human embryo research will be unlikely to get off 
the ground, which is particularly unfortunate in the CRISPR context because 
a number of research projects that could eradicate life-threatening diseases 
from the human genome may be abandoned.  Moreover, even if scientists 
were to successfully circumvent this hurdle, they would still be forced to 
navigate the incredibly convoluted regulatory regime the United States 
cobbled together decades ago to have a chance of getting a product to market. 
C.  The Current State of Affairs for Regulation 
of Biotechnology in the United States 
The United States’s current regulatory regime for biotechnology is 
woefully ineffectual and, despite recent efforts to modernize this process, 
remains outdated and inefficient.  This section gives a snapshot of the current 
state of biotechnology regulation, beginning with a brief historical overview 
and ending with the most recent updates to the system recommended by the 
Obama administration. 
In 1986, the White House Office of Science and Technology Policy 
(“OSTP”) was tasked with determining how to regulate the then-hot-ticket 
biotechnology trend, recombinant DNA.131  The OSTP decided that writing 
new regulatory laws was unnecessary and opted instead for a system known 
as the “Coordinated Framework,”132 which gave regulatory authority to three 
federal agencies:  the Food and Drug Administration (FDA) under the 
Federal Food, Drug, and Cosmetic Act; the Environmental Protection 
Agency (EPA) under the Federal Insecticide, Fungicide, and Rodenticide 
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Act, the Toxic Substances Control Act, and pollution-control statutes; and 
the U.S. Department of Agriculture (USDA) under the Federal Plant Pest 
Act.133  The OSTP reasoned that this framework would “ensur[e] the safety 
of biotechnology research and products” because it was thought to 
comprehensively cover the relevant federal agencies and provide a clear 
framework for the responsibilities of each.134  This framework “was expected 
to evolve in light of experience, and modifications to the framework were 
anticipated.”135  Since its publication in 1986, however, the framework has 
remained largely the same.136 
Recognizing that the rapid advancement of biotechnology required a new, 
modern system capable of adapting to future products, the Obama 
administration directed the OSTP to revisit the framework and propose 
updates.137  Unfortunately, these updates, published shortly before President 
Obama left office in January 2017, do not propose any substantive changes 
to the Coordinated Framework.  Rather, the lengthy document “lists a series 
of hypothetical biotech products and explains how each agency might 
regulate them.”138  And given the length of time it took for President Trump 
to name an OSTP director,139 it appears unlikely that major changes to the 
Coordinated Framework will take place in the near future. 
Understanding the current state of biotechnology regulation, restrictions 
on human embryo research, and promise of CRISPR-developed therapeutics 
illuminates the need for clearer regulation aimed at enhancing scientific 
discovery without compromising ethical boundaries.  This background 
information is also critical to understanding and evaluating proposals for 
streamlining biotechnology regulation. 
II.  PROPOSALS FOR REGULATION OF BIOTECHNOLOGY AND PATHWAYS 
FOR ETHICAL HUMAN EMBRYO RESEARCH 
Given the extraordinary promise of CRISPR, as well as the possibility for 
abuse of the technology, its regulatory pathway demands a comprehensive 
overhaul.  Strong, clear regulatory oversight is often seen by the 
biotechnology industry as one of the necessary components for high levels 
of investment and innovation.140  A recent report on the state of 
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biotechnology globally states, “[a] strong regulatory environment creates the 
conditions for the production and sale of high quality products and 
technologies.”141  Part II.A examines the regulatory options available for 
CRISPR—and biotechnology as a whole—by looking at the status quo and 
current proposals for modernization.  Part II.B considers proposals for 
regulating human embryo research, and Part II.C details a proposal that 
attempts to merge the two. 
A.  Proposals Aimed at Maintaining or Altering the Current System of 
Biotechnology Regulation Within the United States 
A number of proposals have been put forth for updating the current system 
of biotechnology regulation in the United States.  This section looks at some 
of the more promising ideas that could be fairly and easily incorporated into 
the existing regulatory structure. 
1.  Regulators Could Opt to Maintain the Existing Regulatory Framework 
to Avoid Disturbing the Status Quo 
The first option for regulating CRISPR is to maintain the status quo—the 
Coordinated Framework approach.  Under this approach, the FDA, EPA, and 
USDA would continue to share responsibility for regulating new 
biotechnologies, including CRISPR.  The FDA, for instance, would continue 
to regulate CRISPR-based therapeutic regimes, the USDA would continue to 
regulate genetically modified organisms (GMOs) related to livestock and 
agricultural crops, and the EPA would continue to regulate crops with 
enhanced pesticidal traits.142  Importantly, the U.S. regulatory scheme would 
maintain its product-oriented focus, with the critical attention paid to the end 
product, as opposed to the regulatory scheme in, for example, Canada is 
process-oriented with a focus on how the biotechnology product is 
created.143 
Proponents of the Coordinated Framework believe that this regulatory 
scheme has two distinct advantages:  First, a number of existing laws cover 
the products that could be affected by CRISPR.144  Accordingly, the 
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Coordinated Framework, both at its conception and today, has “the advantage 
that [the agencies] provide more immediate regulatory protection and 
certainty for the industry than [is] possible with the implementation of new 
legislation.”145  Second, proponents of the framework believe that its stated 
objectives are well supported by the existing regulatory scheme, namely that 
there is a “[c]onsistency of definitions and regulatory scope[, c]lear 
establishment of lead and supporting agencies with a mechanism for effective 
interagency communication[, c]onsistency of statements of information to 
support review[, c]omparably rigorous reviews[, and t]ransparency of [the] 
review process.”146  Consequently, advocates of the framework see no 
pressing reason to overhaul the current regulatory scheme. 
Conversely, opponents of the Coordinated Framework contend that it is 
outdated, inflexible, and incomprehensive, particularly when it comes to 
evaluating genetic engineering technologies.147  In criticizing the 2017 
update to the Coordinated Framework, Professor Jennifer Kuzma of North 
Carolina State University stated, “New [genetic engineering] technologies, 
like . . . gene-editing, and gene-drive systems, as well as novel [genetic 
engineering] products, are challenging regulatory definitions, highlighting 
inadequacies in health and environmental assessments, and revealing gaps in 
agency jurisdiction.”148  Kuzma further contends that the irony of subjecting 
groundbreaking scientific discoveries to an archaic regulatory scheme is 
causing many researchers to lose faith in the system.149 
In leveraging this critique, Kuzma gives the recent example of the FDA’s 
approval of the first genetically engineered mosquito as an Investigational 
New Animal Drug (INAD).150  This mosquito is capable of mating with wild 
mosquitos but, because of a technologically modified gene, most of the 
resulting offspring die in early development.151  Researchers hope that by 
releasing these modified mosquitos into the wild, the overall mosquito 
population will decline and, with it, the prevalence of diseases transmitted by 
mosquitos such as dengue fever, Zika virus, and malaria.152  While the FDA 
has jurisdiction over INADs under the Coordinated Framework, applications 
for this designation typically involve chemicals that are “injected, topically 
applied, or fed to animals to treat or prevent disease . . . [and] are primarily 
reviewed based on safety and efficacy to the target animal.”153  Clearly, an 
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INAD that is genetically engineered to bring about the demise of its own 
population does not fit within these regulatory standards.154  Moreover, the 
eradication of a species could have serious environmental impacts that the 
FDA does not have jurisdiction to evaluate.155  These issues led Kuzma to 
conclude that the status quo for biotech regulation is “outdated, and 
confusing, especially for newer biotechnology products” and “is bound to get 
worse.”156 
Other recent regulatory submissions of genetically altered organisms have 
similarly drawn the ire of Coordinated Framework opponents.  One such 
example is an “anti-browning” white button mushroom engineered at 
Pennsylvania State University,157 which many believed would be regulated 
by the USDA under the Plant Protection Act, an act that gives the agency 
jurisdiction to regulate genetically engineered crops.158  Historically, GMO 
crops such as this mushroom have been modified using transgenic techniques 
in which a “plant pest” is inserted into the genetic material of the original 
crops.159  The vast majority of these types of crops “were made using a soil 
bacterium to deliver a new gene, were modified with a gene taken from a 
bacterium, or both,” which “triggered the ‘plant pest’ regulatory 
mechanism.”160  Many of these techniques are no longer used because 
CRISPR allows scientists to modify the genome of agricultural products 
without inserting DNA from another species.161  This technological shift 
means that crops edited using CRISPR fall outside of the USDA’s definition 
of GMO, and subsequently out of the USDA’s jurisdiction.162  But because 
of the underinclusiveness of the Coordinated Framework, neither the FDA 
nor the EPA had jurisdiction over these sorts of GMOs, which enabled the 
mushroom to escape regulation.163  While the mushroom itself may not pose 
health threats, it has hit a nerve among opponents of the Coordinated 
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Framework who worry that future CRISPR-created products may not be so 
harmless.164 
Finally, there is a camp in the Coordinated Framework corner that does 
not necessarily advocate for the system but rather recognizes that an overhaul 
of either domestic or international policy is unlikely given lawmakers’ 
current unwillingness to prioritize this sort of regulation.165  These 
“pragmatists” generally believe that the discussion of possible regulatory 
solutions is important but note that “without a change in the current 
atmosphere there is little likelihood of success.”166  When pressed to consider 
the possible ethical and national security consequences of this deterministic 
attitude, these pragmatists contend that widespread use of the technology will 
enable rapid mitigation of potential threats, whereas overregulation would 
limit the ability of the government to respond quickly in the face of such 
threats and thus hold that the current state of affairs is sufficient, even if it is 
less than ideal.167 
2.  The National Academies of Science Recommend Restructuring 
the Regulatory System to Allow for a Single Point of Entry 
for All Biotechnology Product Applications 
An alternative to scrapping the entirety of the Coordinated Framework is 
to revamp the existing framework to improve the efficiency of the approval 
process.  The NAS adopted this position in the 2016 report Preparing for 
Future Products of Biotechnology.168  In evaluating the current state of the 
U.S. biotechnology regulatory system, the NAS found the overall regulatory 
regime to be effective but identified as a major concern the ability of the 
system to evaluate new products quickly as biotechnology product 
applications proliferate.169  Accordingly, the NAS recommends a stratified 
regulatory scheme where a single point of entry categorizes the proposed 
products based on risk-analysis methodology: 
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Figure 1170 
 
As depicted in Figure 1, the advisory body at the entry point would 
categorize proposed products as either unregulated,171 familiar or 
noncomplex, unfamiliar or complex, or unfamiliar and complex in 
comparison to already approved biotechnology products.172  Each group is 
then subject to various levels of scrutiny based on the potential risk the 
product category poses, with unfamiliar and complex product applications 
subject to the most rigorous review process.173  Conversely, more familiar 
products would be eligible for “a more expedited process . . . under the 
assumption that relevant risk-analysis processes are well established.”174 
The NAS proposal also provides for postapproval monitoring systems that 
mirror the initial categorization of the products.  The unfamiliar and complex 
products, for example, would be subject to higher standards of reporting and 
audit once they are on the market than would the familiar or less complex 
products.175  Given the more stringent requirements both pre- and post-
approval for unfamiliar and complex products, one potential problem 
concerns how the products are categorized.  To deal with conflicts that may 
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arise during this categorization process, the NAS recommends evaluating the 
products using additional objective criteria, including: 
the degree of confinement and/or containment (greater 
confinement/containment should reduce the likelihood of environmental 
exposure), whether it is living or nonliving (a living product may increase 
uncertainty and unpredictability of the assessment), and reversible or 
nonreversible product deployment (a nonreversible deployment may 
increase the complexity of risk-management measures to mitigate adverse 
effects).176 
Moreover, the NAS prescribes an increased role for participation by 
multiple stakeholders as a way to deal with one of the key criticisms of 
federal agencies:  lack of complete information.177  The higher the degree of 
complexity or novelty ascribed to a product, the greater the participation of 
external stakeholders will be.  For instance, an unfamiliar and complex 
product would likely require the input of a peer review board, expert panel, 
and possibly the public to ensure that the agency is not evaluating the product 
based on incomplete information.178 
The system suggested by the NAS is similar to Canada’s regulatory regime 
for biotechnology products.  In Canada, regulatory authorities assess 
products by first determining whether the genetically modified traits have 
been seen in this species before.179  If the trait is deemed novel, then the 
product will undergo a stringent regulatory process to assess human and 
environmental safety, whereas products with nonnovel traits are expedited 
through the review process.180  Proponents of this regulatory scheme claim 
the system “promotes efficiency, coherence and uniform application of 
standards because no matter what technologies are used, regulatory 
intervention will apply only to novel plants and foods.”181  Notably, this 
system does not specifically regulate products created using human embryo 
research but does provide a conceptual framework for one of the ways in 
which government actors may think about such regulation. 
3.  Some Experts Call for the Expansion and Adoption of International 
Agreements Governing Gene-Editing Technologies 
Given the cross-border effects CRISPR research could have, many have 
called for an international regime to govern the use of CRISPR.  This section 
details the current and proposed international agreements aimed at global 
cooperation. 
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In international law, the most widely accepted agreement is the United 
Nations Convention on Biological Diversity,182 which is set forth in the 
Cartagena Protocol on Biosafety (“Cartagena Protocol”), and the Nagoya 
Protocol on Access to Genetic Resources and the Fair and Equitable Sharing 
of Benefits Arising from Their Utilization (“Nagoya Protocol”).183  The 
Cartagena Protocol, adopted in 2000, “aim[ed] to ensure the safe handling, 
transport and use of living modified organisms (LMOs) resulting from 
modern biotechnology that may have adverse effects on biological diversity, 
taking also into account risks to human health.”184  The Nagoya Protocol, 
adopted in 2011, is essentially a follow-up to the Cartagena Protocol, setting 
out further compliance provisions in an effort to even the genetic engineering 
playing field.185 
The United Nations developed the Cartagena Protocol in an effort to 
address concerns about the impact genetically modified organisms may have 
on the environment.186  The terms of the agreement require parties to “notify 
one of the U.N.’s International Biosafety Clearing-Houses and any affected 
nations about activities that may lead to movement of living modified 
organisms with potential adverse effects on biological diversity or human 
health.”187  Today, policymakers are exploring whether this language can be 
extended to govern the use of genetic engineering for therapeutic 
purposes.188  Because of the sheer number of countries that are parties to the 
agreement, some policymakers argue that this “modernization” approach 
would be a relatively efficient way to regulate CRISPR on a global scale.189 
Critics of this approach caution that the modernization of existing 
protocols may not make a huge impact on the international framework of 
biotechnology regulations for three reasons.  First, many of the signatories to 
these protocols are middle- or low-income countries, and while these 
countries have used these agreements as frameworks for their own national 
regulatory regimes, many of them lack the resources to enforce these 
regulations.190  Second, nations with high rates of CRISPR research, such as 
the United States, are not signatories to the agreements, which means that 
“the United States does not have a clear policy for collaborating with other 
countries with divergent systems of governance.”191  Finally, those with 
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malicious intent would be unlikely to operate within the confines of 
international—or even domestic—agreements, rendering these sorts of 
agreements ineffective at dealing with national security problems.192 
Critics further argue that the jurisdiction of the Cartagena and Nagoya 
Protocols is not comprehensive enough to cover modern biotechnology; that 
“it is difficult to integrate social, political, and ethical norms of different 
countries into a single policy[;] and that developing international systems of 
governance may require substantial resources that may take away from 
developing strong national-level oversight.”193  These concerns led experts 
to call for new transnational governance based on concepts of soft power at 
the International Summit on Human Gene Editing in 2015.194  And while 
policies stemming from a soft power would not be legally enforceable, 
“[t]heir advantages include the fact that they are voluntary, cooperative and 
reflexive; can be adopted or revised relatively quickly; allow many different 
approaches to be tried simultaneously; and can be gradually ‘hardened’ into 
more formal regulatory oversight.”195  Proponents of this approach argue that 
mobilizing the international community and enacting these sorts of policies 
may give these international agreements a foundational position, which 
means that individual nations would look to these agreements as they draft 
their own individual regulations.196  This scenario would increase the 
efficacy of such policies given the general lack of enforcement power 
inherent to international agreements.197 
4.  Rather than Give Specific Structural Recommendations, Some Groups 
Advocate for General Criteria-Based Regulatory Regimes 
A final approach to biotechnology regulation could be to encourage the 
adoption of frameworks that meet a defined set of criteria as opposed to 
advocating for a one-size-fits-all model.  In attempting to define what this set 
of flexible criteria might look like, researchers for the International Food 
Policy Research Institute (IFPRI) recommended exploration of the following 
categories:  effectiveness, economics, good governance, conformity, and 
legitimacy.198  These categories are further explicated in Table 1 below. 
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Table 1199 
Criterion Aspects
Effectiveness 
criteria 
 Effectively ensuring desired levels of 
environmental and food safety 
 Effectively avoiding regulatory failure
Economic 
criteria 
 Cost-effectiveness:  Achieving desired levels 
of environmental and food safety at lowest 
possible costs 
 Optimal “intensity” of regulation:  Expected 
marginal benefits from regulation equaling 
expected marginal costs 
 Dynamic efficiency:  Creating/protecting 
incentives for innovation
Good 
governance 
criteria 
 Control of special interest capture:  
Regulation is not captured by special interest 
groups (biotechnology industry, 
environmental groups) 
 Fairness:  Acceptable balance of different 
societal interests, and acceptable distribution 
of costs and benefits  
 Voice and accountability:  Processes are 
transparent and provide scope for citizen 
participation; regulatory agencies are 
accountable to citizens and their political 
representatives 
 Control of corruption:  Regulation does not 
create incentives for corruption/has safeguards 
against corruption  
 Rule of law:  Regulations can be enforced 
Conformity 
criteria 
 Regulation conforms with international 
agreements (Cartagena Protocol, WTO) 
 Regulation conforms with regional treaties 
and national constitutions  
 Regulation conforms with international good 
practice standards
Legitimacy 
criteria 
 Input legitimacy:  Regulatory process is 
considered fair, transparent, participatory, and 
accountable 
 Output legitimacy:  Performance of regulatory 
process is considered satisfactory, regulatory 
failures are avoided, and problem-solving 
capacity is in place
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The IFPRI concludes that balancing the perspectives of stakeholders—
such as government, consumers, and industry—with these criteria may be a 
particularly effective approach because introduction of the criteria may 
“help[] rationalize emotional debates, and may narrow down the number of 
options on which different groups disagree.”200 
*          *          * 
The four proposals discussed are representative of the wide range of 
options policymakers must consider, and there are important pros and cons 
for each of these options.  Maintaining the Coordinated Framework, for 
instance, would be the path of least resistance but may contribute to greater 
inefficiencies over time.  Restructuring the Coordinated Framework to 
incorporate a single point of entry may be better for product developers but 
would require political will that may be challenging to rustle up in the current 
political climate.  International consensus building would mitigate fears of 
misuse of gene-editing technology in developing nations but lacks the force 
of law.  And finally, criteria-based governance approaches are good for 
establishing norms but lack structural recommendations.  Policymakers must 
prioritize the outcomes they wish to see from a restructured regulatory regime 
and mix and match the aforementioned proposals to maximize the potential 
of achieving those outcomes. 
B.  Regulatory Options for Increasing Oversight 
of Human Embryo Research 
In addition to the general debate over how to increase the efficiency of the 
U.S. biotechnology regulatory system, there is great need to clarify the laws 
and regulations governing the use of human embryos in scientific and 
medical research.  This issue is made even more challenging by the general 
lack of information available regarding current research being done on 
human embryos because “[n]o country is systematically making public any 
overview of the embryo research performed on its territory.”201  This section 
first explores the option of banning human embryo research entirely, then 
discusses licensing systems implemented by the United Kingdom and 
Belgium, and concludes with a discussion of possible ways in which 
scientists may secure funding for such research. 
1.  Opponents of Human Embryo Research 
Advocate for a Complete Ban 
The first option is to simply not allow research on human embryos, which 
is a position endorsed by “[s]ome scientists and public interest groups, 
including the United Nations Educational Scientific and Cultural 
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Organization (UNESCO).”202  Opponents of human embryo research, who 
advocate this approach, note that it is not necessary for medical purposes 
because of the ability to prescreen embryos for genetic defects.203  
Proponents of human embryo research, in response to this position, state that 
current IVF procedures do not guarantee that all embryos will be free of 
genetic defects.204  These proponents also argue that gene editing has the 
potential to not only eradicate disease in the immediate offspring of a couple, 
but also in future generations of the genetic line because of its unique ability 
to alter heritable traits.205 
Opponents of human embryo research also argue that the research is 
morally impermissible because of the harm that may befall what many see as 
potential life.206  Moral philosophers question the soundness of this 
proposition, however, by asking how it is that an embryo—an entity that is 
devoid of experiences or desires—can be harmed.207  These philosophers 
also point out that many jurisdictions allow for both abortion and elimination 
of unwanted embryos following IVF, which underscores their position that 
many current practices would not be upheld if the concern of harming 
embryos were paramount.208  Finally, the philosophers of this camp point to 
the fourteen-day rule209 as a means of ensuring that no “future people” are 
harmed by genetic research.210  Even still, questions persist as to whether use 
of human embryos for genetic research inappropriately puts scientists in 
divine shoes. 
2.  Internationally, Government-Run Licensing Programs Have Been 
Effective at Monitoring Human Embryo Research 
The European Union’s position on human embryo research is set forth in 
the European Convention on Human Rights and Biomedicine, which bans 
the creation of human embryos for research purposes.211  Several countries 
within the European Union, notably Belgium and the United Kingdom, 
declined to sign the Convention because they found the terms too 
restrictive.212  Belgium in particular wanted the freedom to establish its own 
regulatory regime regarding human embryo research, which it did in 2003 
with the enactment of the Law on Research on Embryos In Vitro.213  This 
law created a federal commission charged with evaluating proposed research 
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projects involving the use of human embryos and determining which projects 
meet the law’s stringent requirements.214  The law includes: 
[A] number of applications that are forbidden, such as reproductive cloning, 
eugenics, sex selection for nonmedical reasons, implantation of human 
embryos in animals, and creation of chimeras or hybrids.  Research on 
embryos is allowed for up to 14 days (freezing period excluded) and must 
be based on the most recent scientific findings and conducted according to 
the appropriate scientific methods.  The research must be performed in a 
laboratory of a university that is recognized as a center for reproductive 
medicine.  No other research method can be equally effective to obtain the 
same results.  Embryos subjected to research must be destroyed unless the 
research had a therapeutic goal for the embryo, or when it concerns mere 
observation that does not harm the embryo’s integrity.215 
Once a proposed research project meets these requirements, it is free to 
conduct the planned research. 
The United Kingdom’s Human Fertilisation and Embryology Authority 
(HFEA) similarly regulates the use of human embryos in research.216  The 
HFEA requires that researchers obtain a license for every project; research 
meets one of the purposes of the Human Fertilisation and Embryology Act 
of 1990;217 donors have consented to donating for research purposes; 
embryos involved in research cannot be implanted in a woman; and embryos 
are not permitted to develop past fourteen days.218  This process also 
mandates approval from an HFEA-approved ethics committee before 
submitting an application for a license.219  Once a research team submits an 
application, the HFEA then commissions peer reviews and carries out clinic 
inspections to ensure the standards of the Human Fertilisation and 
Embryology Act are met.220  If these criteria are fulfilled, the research team 
is granted a license—valid for up to three years—to conduct the planned 
human embryo research.221 
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3.  Revamping Funding Restrictions Could Lead to Greater 
Government Oversight of Human Embryo Research 
Funding is one of the largest issues surrounding human embryo research 
in the United States.  As discussed, the Dickey-Wicker Amendment currently 
bans federal funding of human embryo research.222  Researchers within the 
United States may, however, conduct gene-editing research provided they 
obtain private funding.  Critics of this system argue that enabling private 
funding of human embryo research diminishes the government’s ability to 
regulate research that could have far-reaching impacts on the country and the 
world.223  They argue that lifting the federal funding ban would give 
American regulators “greater scientific and ethical oversight,” permit 
“greater scrutiny of the value of this research through the peer review 
system,” and potentially “create incentives to direct research toward health 
issues that have important implications for children.”224  Indeed, a recent 
survey of scientists found that the scientific community writ large supports 
both federal funding of human embryo research and the creation of human 
embryos for such research purposes.225  This change would require 
legislative overhaul, however, and it is unlikely that politicians at this 
juncture in time will champion the cause of human embryo research, which 
means that there is very little political will to effectuate such a change.  This 
stubbornness persists despite findings from as recently as 2016 that 60 
percent of Americans find “[m]edical research using stem cells obtained from 
human embryos” morally acceptable.226 
C.  The Evitt Proposal Advocates for a Comprehensive Overhaul 
That Incorporates Human Embryo Research Within 
the Broader Biotechnology Regulatory Framework 
Rather than have two disparate systems—one for human embryo research 
and one for biotechnology regulation—Stanford University researchers 
proposed a unified system in which government regulation begins at the 
research stage and continues through the distribution phase.227  The 
researchers argue that a separate framework is necessary for CRISPR 
technologies, as opposed to other forms of biotechnology, because of its 
“unprecedented promise and peril.”228  This framework, referred to here as 
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the “Evitt proposal,” is divided into five phases:  before preclinical research, 
during preclinical research, prior to clinical development, during clinical 
development, and distribution.229 
Phase I occurs during the preclinical research stage, at which point 
researchers must engage with agencies and CRISPR-specific oversight 
committees to ensure that the proposed CRISPR application has a reversal 
mechanism, does not contain a gene drive,230 and will address either 
monogenic diseases with no treatment alternative or diseases in which 
CRISPR technologies will drastically decrease embryonic loss due to genetic 
screening.231  If these research objectives are met, product developers move 
onto Phase II—the “during preclinical research” phase.232  Here, researchers 
would need to show proof of concept to give the research team a chance to 
refine study design in nonhuman cells and animal models, which would also 
“lower the ethical burden of [these] experiments by minimizing embryo 
destruction.”233 
Phase III—preclinical development—requires that the research team 
obtain the consent of the individuals providing genetic material, and Phase 
IV—clinical development—essentially mirrors the drug-approval process 
currently mandated by the FDA.234  Finally, in Phase V, mandatory 
multigenerational surveillance trials should be established to monitor the 
long-term effects of CRISPR therapeutics.235  The Stanford team contends 
that this robust regulatory framework will de-risk CRISPR research in human 
embryos in a manner that balances the lifesaving benefits these therapeutics 
may have with the serious risks posed to the human genome.236  Moreover, 
the team contends that this framework deals with many of the ethical 
dilemmas posed by CRISPR, and, accordingly, once this is in place there will 
no longer be a need for the federal funding ban.237 
*          *          * 
The options on the table for regulation of CRISPR in relation to its reliance 
on human embryo research range from an overhaul of the current 
Coordinated Framework system to embryo-specific licensing programs 
completely separate from the biotechnology regulatory process to integrated 
regulatory schemes like the Evitt approach that endeavor to bridge human 
embryo licensing with biotechnology regulation.  Given the importance of 
CRISPR, and the rapid pace at which the technology is developing, it is 
important to settle on a regulatory scheme soon to ensure readiness for some 
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of the tough ethical and scientific questions that CRISPR will inevitably 
pose. 
III.  REGULATION OF CRISPR-CREATED GENE-EDITING PRODUCTS 
SHOULD BE GOVERNED BY AN UPDATED REGULATORY 
REGIME THAT STREAMLINES THE APPLICATION PROCESS FOR 
PRODUCT DEVELOPERS WHILE SIMULTANEOUSLY GIVING 
THE GOVERNMENT INCREASED OVERSIGHT 
Given the numerous proposals available to policymakers, it is important to 
consider which options will increase the efficiency of product applications 
without sacrificing the standards of safety and efficacy that are the hallmarks 
of the current Coordinated Framework regime.  This Part discusses why the 
status quo must be overhauled to allow for regulation and proposes a 
regulatory scheme that incorporates licensing for human embryo research as 
a component of a process-oriented regime. 
A.  The Current Coordinated Framework Regime 
Is Outdated and Inefficient 
Critics of the Coordinated Framework are correct that this regulatory 
system is impractical given the current acceleration of biotechnology 
development across the United States238 for four reasons.  First, the current 
regime is incapable of comprehensive regulation.  As evidenced by the ability 
of the nonbrowning mushroom to slip through the cracks, the Coordinated 
Framework does not comprehensively regulate all new products made using 
CRISPR.239  These products escape regulation because they do not fit the 
USDA’s outdated definition of GMOs—the current framework requires that 
some form of “plant pest” be introduced into the product to trigger regulatory 
oversight.  Because CRISPR does not require that the DNA of another 
species be engrafted into the plant or crop at issue—and typically only alters 
the product’s own DNA—it may be argued that there is a much lower risk 
involved and thus regulation is not as critical.  This position dangerously 
assumes (or at least makes it seem very unlikely) that any alterations made 
within the DNA of a product are incapable of leading to adverse health 
outcomes for humans and animals that ingest the product.  Study of the 
modern genome shows that small genetic mutations—even the alteration of 
just one base pair within a DNA sequence—can have disastrous effects on 
the health of an organism, and there is no research indicating that these poor 
health outcomes will not be passed on to end users of the product.  
Accordingly, regulation of the process used to create products intended for 
consumption is critical. 
Moreover, the Coordinated Framework cannot, at present, regulate the 
products of research using human embryos because the three relevant federal 
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agencies do not have jurisdiction over embryos.  Human embryo research 
clearly falls outside the purview of the USDA and EPA, and the FDA is 
currently blocked from even considering proposals that involve human 
embryo research at any point.240  This means that Congress has blinded the 
FDA to work that is being done in this field, thereby limiting the agency’s 
ability to meaningfully regulate any product or research process involving 
human embryos.  Additionally, there is no one to hold accountable for the 
lack of regulation because there have not yet been any laws passed regarding 
human genomic editing, and the only real restrictions placed on scientists 
stem from consensus-driven agreements in the global scientific community 
that lack the force of law.241 
Second, the current regime is confusing for product developers.  Because 
of the number of federal agencies involved, and their overlapping statutory 
jurisdictions and mandates, developers are left in the dark as to which laws 
might govern the regulation of their products.  This inability to plan for 
regulation is extremely unfair to developers who invest millions—if not 
billions—of dollars researching and developing242 groundbreaking and 
potentially lifesaving products.  This regulatory opaqueness has three 
important ramifications.  First, product developers are unable to design 
research in ways that will meet the standards of the agency they will 
eventually defend their products to, which means small technicalities in a 
research design plan that leave the researcher unable to answer questions 
pertinent to the applied statute may result in a denied application.  Second, 
on top of the exorbitant sums spent on research and development, product 
developers expend additional money to determine which federal agency is 
the appropriate regulatory body for their product, and may, in the end, be told 
that because of the novelty of the product, none of the relevant federal 
agencies have jurisdiction.  In this way, product developers may be dissuaded 
from creating novel therapeutics.  Finally, product developers, particularly 
those using human embryo research, are at the mercy of their investors.  To 
successfully fund a project, the developers need to have an informed plan for 
how the product will be priced, marketed, and distributed postregulation.  
The Coordinated Framework’s opaqueness muddies a developer’s ability to 
estimate the restrictions that may be placed on the product, which in turn 
affects the product’s end-distribution network and drives up research and 
development costs.  These costs are then passed on to the consumer and 
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contribute to the exorbitant prices of medication in the United States.  This 
system is consequently unfair to developers, investors, and consumers. 
Third, the current regime results in unnecessary delays, which will only 
worsen as biotechnology applications increase.  Because the regulatory 
jurisdictions of the FDA, EPA, and USDA overlap under the Coordinated 
Framework, some product applications require agencies to spend an 
unnecessary amount of time determining who is the most appropriate 
regulatory body.  It is not hard to imagine scenarios in which one regulatory 
body nears the end of regulatory review only to realize that another agency 
should have been reviewing the product, which resets the entire process.  
These inefficiencies are likely to increase as biotechnology product 
applications increase in the coming decade and lead to misused government 
funds and unnecessary delays in getting lifesaving treatments to consumers. 
Finally, the Coordinated Framework is too focused on the end product.  It 
ignores the process used to create these products to the detriment of the 
public.  As evinced by the long-standing debates surrounding human embryo 
research, there is a significant amount of public investment in the question of 
how a product is developed.  The current system does not enable federal 
agencies to consider the process used as part of their review, which could 
lead to oversight of important health and safety consequences when 
compared to systems that pay more attention to process.  In the Canadian 
system, for example, the regulatory scheme is essentially product-focused 
but regulators put a large emphasis on the novelty of the trait introduced 
through gene editing.243  This inquiry requires that Canadian regulators spend 
more time considering the development process and, subsequently, gives 
them greater insight into some of the ethical concerns that may arise out of 
approval of a gene-edited product.  The current regulatory system in the 
United States ignores process to its detriment. 
Accordingly, the Coordinated Framework is outdated and in desperate 
need of an overhaul to address unique problems associated with gene-edited 
products in the twenty-first century. 
B.  Regulation Is Necessary to Keep American Product 
Developers Competitive in the Global Environment 
and to Protect the Health and Safety of Consumers 
Leaving the gene-editing market to regulate itself is an unwise strategy 
because it will exacerbate the ethical and national security questions 
concerned with modification of the human genome.  To date, the scientific 
community has done a laudable job of regulating the use of gene-editing 
technology despite the global absence of law mandating that they do so.  For 
example, following the International Summit on Gene Editing in 2015, the 
organizing committee released a statement supporting a ban on any CRISPR 
research that would permanently alter the human germline until there has 
been further proof of the safety and efficacy of such procedures, and broad-
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based societal consensus has been reached regarding the ethics of germline 
editing.244  While scientists around the world have, to date, respected this 
moratorium, it is only a matter of time before enterprising labs or companies 
resolve to push the barriers in the name of either innovation or profit.  
Without legal consequences for these actions, there is no assurance that 
important ethical boundaries will remain intact.  Moreover, given the 
widespread accessibility and low cost of CRISPR, a complete ban on use of 
these technologies will be ineffective and undesirable because of the 
promising outcomes they could have—if properly regulated—on human 
health. 
There may be a fear among scientists that forcing regulations on CRISPR 
will result in increased attention to the technology, subsequent public outcry, 
and ultimately a legislative ban on the technology.  While there is always a 
risk of backlash when new technologies are brought to the attention of the 
public, recent studies indicate that Americans are more open to gene editing 
than ever before.245  Additionally, careful framing of the need for regulation, 
which is grounded in promoting safety and is ethically reasonable, will likely 
quell the fears of members of the public who may perceive CRISPR as a 
threat.  Accordingly, prior to launching a campaign for regulation, careful 
consideration should be placed on messaging the need for regulation, but 
concerns regarding public outcry should not dissuade scientists from seeking 
regulation.  Thus, the best path forward is to regulate the use of CRISPR 
technology.  But if the Coordinated Framework is ineffective, what is the 
best path forward? 
C.  Specific Regulatory Recommendations Focus on Creating a Single 
Point of Entry for Biotechnology Products and Creating a 
Licensing Subcommittee for Human Embryo Research 
While a novel or updated regulatory regime should consider the criteria 
outlined by the IFPRI,246 a criteria-based system in and of itself leaves too 
much room for interpretation.  Rather, these criteria should be considered 
foundational components of a regulatory regime that incorporates both the 
NAS proposal for a single point of entry and the Evitt proposal.  Using this 
approach, the United States would be able to regulate CRISPR—and other 
emerging biotechnologies—in a manner that accounts for both the safety 
concerns associated with CRISPR-created products and the ethical dilemmas 
posed by the processes relied upon by CRISPR researchers, particularly in 
the field of human embryo research.  Accordingly, the new regulatory regime 
should incorporate a licensing program for human embryo research on the 
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front end of the single-entry-point framework, giving the federal government 
greater oversight of human embryo research.  The following framework is 
organized as a comprehensive, beginning-to-end approach with an eye 
toward incorporation of CRISPR into the larger biotechnology regulatory 
scheme, a desire to utilize as many of the existing regulatory bodies as 
possible, and recognition that the government must be involved in the 
research process for germline cell editing. 
1.  Increasing Efficiency Is Dependent on the Creation of a Single 
Point of Entry for All Product Applications 
The most important component of an updated regulatory system for 
biotechnology, and CRISPR in particular, is a single point of entry.  
Researchers affiliated with academic institutions and companies looking to 
develop novel therapeutics using CRISPR need a straightforward path for 
determining which regulatory body is responsible for the regulation of either 
a research plan or a new drug.  Given the high overhead costs247 associated 
with drug development, institutions looking to break into this field should 
not be additionally burdened by excess legal fees that are expended with the 
sole goal of trying to determine which regulatory body is the most 
appropriate.  Rather, the government should perform this sorting function. 
The single-point-of-entry framework would not only increase the 
efficiency of the biotechnology application process for product developers 
but would also be the most appropriate for CRISPR given the technology’s 
wide-ranging applicability.  As discussed, CRISPR’s ability to alter the genes 
of any organism means that some of the resulting products may appropriately 
fall under the regulatory purview of the USDA, FDA, or EPA.  Moreover, 
certain products may escape regulation altogether because the authority 
delegated by Congress via statutory mandates was not specifically written 
with technologies like CRISPR in mind and may therefore be 
underinclusive.248  Accordingly, the creation of a single point of entry for all 
CRISPR-based product applications would enable regulators to more 
appropriately assess which federal agencies and corresponding legislation 
govern the approval process of such products. 
a.  The Single-Point-of-Entry Committee Should Be Staffed with 
Individuals from a Diverse Set of Backgrounds to 
Ensure Ethical, Scientific, and Regulatory Integrity 
The success of a single-entry-point regulatory scheme is highly dependent 
on a purposeful structuring of the entry point itself.  Creation of an entirely 
new federal agency, for instance, would be imprudent because it would not 
solve the problems of efficiency—seemingly inherent to federal agencies—
that currently slow approvals of biotechnology.  Rather, the single entry point 
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should be structured to allow for maximum flexibility, and therefore 
efficiency, without compromising scientific integrity.  Accordingly, this 
Note proposes the creation of a central committee that serves as the 
gatekeeping body at the mouth of the single entry point.  The following 
section first elaborates on the benefits of such a committee followed by a 
discussion on the suggested membership. 
A committee comprised of leading ethicists, scientists, regulators, and 
legislators would be the most effective way to manage the single-entry-point 
system.  By putting scientific thought leaders familiar with the cutting edge 
of technology on such a panel, developers would be assured that product 
applications are not misunderstood for lack of scientific knowledge.  At the 
same time, the public at large would be appeased by the presence of ethicists 
and legislators, knowing that the conversation surrounding possible gene-
editing products would include discussion on the ethical questions posed by 
such technologies.  Finally, seasoned regulators would be able to weigh in on 
which federal agency has authority to regulate such a product, adding a level 
of regulatory know-how other committee members might lack. 
The Australian Research in Human Embryos Act (RIHE Act) mandated 
the creation of a similar committee tasked with granting—or withholding—
licenses for human embryo research.249  By law, the committee must be 
comprised of an expert in the regulation of ART, a member of the Australian 
Health Ethics Committee, an expert in research ethics, an expert in a relevant 
area of research, an expert in a relevant area of law, an expert in consumer 
health issues relating to disability and disease, an expert in consumer issues 
relating to ART, and an embryology expert.250  Of course, the single point of 
entry proposed here would require committee members to cover a broader 
array of biotechnology proposals, but subcommittees with targeted expertise, 
like the one created by the RIHE Act, could be created ad hoc for particularly 
complex product applications. 
The biggest drawback to such a committee is that it would need to be 
created by new legislation,251 and given the current political climate it is 
unlikely that bipartisan support sufficient to approve such a bill could be 
mustered.  This sort of legislation would likely require grassroots support and 
substantial media coverage to gain traction, and given the complexity of 
CRISPR research in particular it seems unlikely that such a movement will 
take shape organically.  Rather, more research like the trials conducted by 
OHSU in 2017252 will need to be published to push this conversation to the 
forefront of national debate and encourage citizens to put pressure on 
legislators to more effectively regulate CRISPR.  At such time, the ability of 
legislators to quickly draw on regulatory proposals will be critical. 
 
 249. Embryo Research Licensing Committee, NAT’L HEALTH & MED. RES. COUNCIL, 
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b.  The Single Point of Entry Will Allow for Tailored Oversight Following 
the Initial Categorization of the Proposed Research Plan 
In addition to giving product developers more insight into the regulation 
of CRISPR-created products, the single-entry-point sorting function enables 
regulators to appropriately scale up or scale down oversight of research plans 
depending on the novelty of the proposals.  The Evitt proposal, for instance, 
recommends that regulation take place in each of the following five phases:  
before preclinical research, during preclinical research, prior to clinical 
development, during clinical development, and distribution.253  For novel, 
complex research plans, including those involving human embryos and 
germline editing, the government’s level of involvement at each of these 
stages should be relatively high.  For less complex, more familiar proposals, 
however, there is no need to burden product developers with unnecessary 
regulation.  Subsequently, the Evitt proposal is bolstered by an incorporation 
of the NAS’s proposed single point of entry because the single-entry-point 
committee can weigh the risks of the proposed CRISPR research and tailor 
the necessary level of oversight accordingly. 
2.  Proposals for Research Involving Human Embryos Should Be 
Submitted to the Committee at the Single Point of Entry 
to Increase Government Oversight from the Beginning 
Beyond increasing efficiency and ensuring appropriate expertise, a single 
entry point also enables regulators to more easily move to a process-oriented 
regulatory system, which is critical for establishing a beginning-to-end 
regulatory scheme for CRISPR research involving human embryos.254  As 
currently implemented, the Coordinated Framework focuses purely on end 
products.  It is the product alone that is evaluated for safety and efficacy once 
it has been submitted for review with no attention paid to the processes used 
to create that product.  For biotechnologies that do not pose significant 
process-related ethical dilemmas, this system is appropriate.  But for 
technologies like CRISPR that may implicate ethical questions because of 
the process used to create the end product, the Coordinated Framework is 
wholly inapt. 
Given CRISPR’s great potential for curing debilitating diseases, and the 
need for the use of human embryos in developing lifesaving therapeutic 
techniques, it is imperative that researchers be allowed to use human embryos 
in research.  A complete ban of human embryo research would not only 
prevent lifesaving cures from being developed, but also harm the United 
States’s competitive position in the world of biotechnology.  Because of the 
possible misuse and abuse of human embryos in this research, however, it is 
critical that the government be involved. 
 
 253. See Evitt et al., supra note 227, at 28. 
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Under this proposed framework, any researcher intending to use CRISPR 
technology to develop therapeutics using human embryos during the research 
process would be required to first submit an application to the single-entry-
point committee.  The committee, or more appropriately a subcommittee 
dedicated to evaluating proposals involving human embryo research, would 
then evaluate the application and balance the need for the proposed 
therapeutic against ethical concerns.  If the application is accepted, the 
committee would then be responsible for stipulating the licensing terms for 
human embryo research and ensuring these terms are adhered to throughout 
the course of the research. 
Involving regulatory bodies at the outset of product research and 
development—particularly when the research involves human embryos—is 
an important step for regulating CRISPR technology.  Use of CRISPR to edit 
human germline cells could possibly lead to severe long-term consequences 
for human evolution,255 and passively allowing scientists to engage in this 
sort of research, provided they obtain private funding, does little to assuage 
concerns.  Society would be better off in the long run if regulators were 
involved from the outset of research, particularly when scientists plan to 
engage in research that could permanently alter the human genome.  This 
enhanced oversight may even lead to broader public approval of such 
research if citizens are assured that the regulatory system takes into account 
ethical and long-term considerations when evaluating product development 
proposals involving human embryo research. 
a.  The Licensing Program for Human Embryo Research Should Mirror 
Those Adopted in the United Kingdom and Belgium 
Outside of funding restrictions, the federal government largely leaves 
oversight of human embryo research up to the states.256  This disparate 
system is inappropriate because CRISPR research, and gene editing more 
broadly, are not contained by state boundaries.  Rather, the effects of this 
research on the human genome are of critical importance both domestically 
and internationally.  Accordingly, greater oversight by the federal 
government is required when researchers propose studies that could 
permanently alter the human germline. 
To this end, the United States should adopt a licensing program in the same 
vein as Belgium’s system.257  The licensing program would cover all 
proposed studies involving human embryos and ensure that criteria intended 
to prevent unethical research are met.  A licensing system is preferable to the 
status quo because it would enable the government to intervene in possibly 
dangerous research regardless of the funding source.  Moreover, a licensing 
system allows the government to evaluate whether the hypothesized outcome 
of proposed research would lead to significant improvements in modern 
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medicine and supports this research when the possible health benefits 
outweigh the research risks. 
b.  The Federal Funding Restriction for Human Embryo Research 
Should Be Lifted 
An additional strategy for increasing government involvement in the 
regulation of human embryo research is to lift the ban on federal funding of 
research projects involving human embryos.  At present, human embryo 
research in the United States must be privately funded, but if the federal 
government were the only permissible funding source, all proposed studies 
involving human embryos would have to be run by the government for 
approval.  This change would increase government oversight and is an 
important component of the proposed embryo research licensing program. 
Ultimately, a shift away from the Coordinated Framework and toward a 
regulatory system comprised of components from the NAS and Evitt 
proposals will serve citizens, industry, and academia well.  Moreover, 
enabling researchers to obtain licenses and funding through the federal 
government to pursue CRISPR research on human embryos will not only 
give the government more control over the human embryo “market,” but also 
possibly enable researchers to completely eradicate life-threatening diseases 
from the human genome.  Accordingly, the United States should aggressively 
move towards revamped regulation of CRISPR to increase scientific 
innovation and decrease the risks posed by unregulated use of gene-editing 
technologies on the human germline. 
CONCLUSION 
CRISPR is arguably the most important development in the field of gene 
editing to date because of the technology’s accuracy, cost-efficiency, and 
ease of use.  These same factors are, however, what make CRISPR dangerous 
in the wrong hands, potentially leading to harmful manipulation of the human 
genome.  Accordingly, the great power of this technology should not be taken 
lightly.  Rather, governments around the world need to act quickly to rein in 
unethical use of this technology. 
Within the United States, this reconsideration of how biotechnology is 
regulated requires a fresh look at restrictions currently governing human 
embryo research and an increase in the government’s involvement in all trials 
involving human embryo research, particularly when those trials may involve 
permanent alterations to the human genome using CRISPR.  To this end, the 
government should consider eliminating the current Coordinated Framework 
for biotechnology regulation because it is inefficient and simultaneously 
over- and under-inclusive in scope.  In its place, policymakers should 
consider a regulatory framework that enables regulators, experts, and the 
public to be involved from the initial planning stages of products involving 
gene editing. 
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A single-entry-point system in which products are categorized by a 
specialized regulatory body would serve to increase the efficiency of the 
sorting process, lead to more transparency for product developers, and also 
give the government the ability to quash potentially dangerous experiments.  
As a subcomponent of this committee, the government should consider the 
addition of a human embryo research licensing body tasked with evaluating 
proposals involving human embryo research and monitoring these studies to 
ensure ethical boundaries are not crossed.  Then, depending on the initial 
complexity of the study and the novelty of the processes proposed by the 
researchers, the government can choose to either scale up or scale down 
monitoring processes.  In this way, the government will allow for greater 
innovation in the medical field without unnecessarily burdening product 
developers, leading to better health outcomes—and possibly the eradication 
of some of the world’s most vexing diseases. 
 
